Flying start in US for Lundbeck's Lexapro  

US doctors write over 3000 prescriptions for Lexapro in the first two days post launch

Daily broadsheet Jyllands-Posten reports that Lundbeck's second generation SSRI antidepressant Lexapro has made an instant impact on the US market. New figures from IMS Health show that in the first two days since its launch, US doctors made out 3,340 scripts for Lexapro. According to IMS, Lundbeck now has an 18% US market share of newly written prescriptions in the antidepressant sector (combined scripts for Celexa and Lexapro). On the strength of these numbers, investment bank Nordea Securities has concluded that Lundbeck's biggest ever product launch has made an excellent start. Lundbeck aims to make Lexapro the world's most successful antidepressant with a US market share close to 25%.


H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2001, the company's revenue was DKK 7.7 billion (USD 1 billion) and the number of employees approx. 4,000.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×